Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25456795 | 0.99 | ALOX5 (0.48) | ALOX5BCHEACHEHDAC3HDAC1 | |
| Ammonia Solution, Strong SCHEMBL25175634 | 0.98 | ALOX5 (0.47) | ALOX5BCHEACHEHDAC3HDAC1 | |
| Ammonia Solution, Strong SCHEMBL25172939 | 0.88 | ALOX5 (0.51) | ALOX5S1PR1S1PR3S1PR4TSHR | |
| Ammonia Solution, Strong SCHEMBL25175635 | 0.87 | ALOX5 (0.52) | ALOX5S1PR1S1PR3S1PR4TSHR | |
| SCHEMBL25456753 | 0.87 | ALOX5 (0.52) | ALOX5S1PR1S1PR3S1PR4TSHR | |
| Ammonia Solution, Strong SCHEMBL25175603 | 0.85 | SRC (0.44) | ALOX5BCHEACHES1PR1S1PR3 | |
| Ammonia Solution, Strong SCHEMBL25167618 | 0.84 | S1PR1 (0.51) | ALOX5HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL25456750 | 0.84 | NPC1 (0.48) | ALOX5TSHRLMNA | |
| SCHEMBL25456763 | 0.84 | SRC (0.45) | ALOX5BCHEACHES1PR1S1PR3 | |
| Ammonia Solution, Strong SCHEMBL25169881 | 0.83 | RAF1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | ALOX5 134/4885BCHE 4294/4885ACHE 4179/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | ALOX5 165/4885BCHE 4355/4885ACHE 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.